methods for treating individuals with prader-willi syndrome or smith-magenis syndrome

摘要

immediate or prolonged administration of certain potassium-atp (katp) channel openers, optionally in combination with growth hormone, to an individual to achieve innovative pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional results in the treatment of diseases or conditions involving katp channels. Pharmaceutical formulations, methods of administration and dosage of katp channel openers are also provided which achieve these results and reduce the incidence of adverse effects in treated subjects. methods of co-administering katp channel openers with other drugs (eg in combination with growth hormone) to treat human and animal diseases (eg prader-willi syndrome (pws), smith? magenis (sms) and the like.